Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Wilkinson, Peter M
AffiliationDipartimento Medicina Sperimentale e Patologia, Università di Roma, Rome, Italy.
MetadataShow full item record
AbstractThe introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level <12 g/dl) cancer patients undergoing chemotherapy. Increased Hb improves patients' energy level and their ability to perform the activities of daily living, as well as their overall quality of life (QOL). These findings are independent of tumor type and disease status and are comparable in patients receiving nonplatinum- and platinum-based chemotherapeutic regimens. Furthermore, more than a decade of use in clinical trials and by physicians in routine clinical practice has demonstrated that epoetin alfa is safe and well tolerated when used to treat cancer patients with anemia. The availability of epoetin alfa as an alternative to transfusion has changed practices in anemia management; physicians can now treat anemia with the goal of achieving adequate Hb levels to relieve anemia-related fatigue, a major symptom contributing to decreased QOL in cancer patients. Incremental benefit analysis has shown that increasing Hb level from 11 g/dl to 12 g/dl yields the greatest improvement in QOL per 1 g/dl increase in Hb. The demonstrated efficacy of epoetin alfa for increasing Hb levels and improving patient QOL have made this agent a rationale choice for management of cancer-related anemia. Ongoing research will continue to provide new insights into best management of anemia with epoetin alfa in cancer patients.
CitationStandard of care for cancer-related anemia: improving hemoglobin levels and quality of life. 2005, 68 Suppl 1:22-32 Oncology
- Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
- Authors: Voravud N, Sriuranpong V, Suwanrusme H
- Issue date: 2007 Jun
- Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
- Authors: Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M, Epoetin Alfa Study Group.
- Issue date: 2003 Dec
- Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
- Authors: Voravud N, Sriuranpong V
- Issue date: 2005 May
- The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
- Authors: Glaspy J
- Issue date: 1997 Jul
- Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
- Authors: Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L
- Issue date: 2004